Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 2/20 | 0.58 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.52 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.52 |
| ▸ | F10 | P00742 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30435392 | 0.89 | MALT1 (0.56) | MALT1GPR119RIPK1F10TSHR | |
| SCHEMBL10154340 | 0.86 | MALT1 (0.58) | MALT1GPR119RIPK1F10TSHR | |
| SCHEMBL21061582 | 0.85 | GRM1 (0.48) | KDM4EALDH1A1HSD17B10HPGDSMN1; SMN2 | |
| SCHEMBL29500844 | 0.85 | GRM1 (0.48) | KDM4EALDH1A1HSD17B10HPGDSMN1; SMN2 | |
| SCHEMBL30722454 | 0.84 | KDM4E (0.57) | MALT1GPR119RIPK1KDM4EALDH1A1 | |
| SCHEMBL18124121 | 0.84 | KDM4E (0.57) | MALT1GPR119RIPK1KDM4EALDH1A1 | |
| SCHEMBL27722977 | 0.83 | RIPK1 (0.61) | MALT1GPR119RIPK1KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL29426707 | 0.82 | KDM4E (0.56) | MALT1GPR119RIPK1KDM4EALDH1A1 | |
| SCHEMBL5005725 | 0.82 | KDM4E (0.55) | MALT1GPR119RIPK1F10TSHR | |
| SCHEMBL2274636 | 0.82 | KDM4E (0.66) | MALT1GPR119RIPK1KDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858943-B2 | Vasopressin receptor antagonists and products and methods related thereto | Neumora Therapeutics, Inc. (US) | 2024-01-02 | — | — | US | disclosed |
| CN-111479813-B | Triazolobenzazepines as vasopressin V1A receptor antagonists | 吉瑞工厂 | 2023-03-21 | — | — | CN | disclosed |
| EP-3634963-B1 | 1-(2-AZASPIRO[3.3]HEPTAN-6-YL)-5,6-DIHYDRO-4H-BENZO[F][1,2,4]TRIAZOLO[4,3-A][1,4]DIAZEPINE DERIVATIVES AS V1A RECEPTOR ANTAGONISTS FOR TREATING NEUROPSYCHOLOGICAL DISORDERS | BLACKTHORN THERAPEUTICS INC (US) | 2023-02-22 | — | — | EP | disclosed |
| EP-3724192-B1 | TRIAZOLOBENZAZEPINES AS VASOPRESSIN V1A RECEPTOR ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2022-08-03 | — | — | EP | disclosed |
| US-11298363-B2 | Triazolobenzazepines as vasopressin V1a receptor antagonists | RICHTER GEDEON NYRT. (HU) | 2022-04-12 | — | — | US | disclosed |
| US-11186577-B2 | Vasopressin receptor antagonists and products and methods related thereto | BLACKTHORN THERAPEUTICS, INC. (US) | 2021-11-30 | — | — | US | disclosed |
| EP-3724192-A1 | TRIAZOLOBENZAZEPINES AS VASOPRESSIN V1A RECEPTOR ANTAGONISTS | Richter Gedeon Nyrt. (HU) | 2020-10-21 | — | — | EP | disclosed |
| CN-111479813-A | Triazolobenzazepines as vasopressin V1A receptor antagonists | 吉瑞工厂 | 2020-07-31 | — | — | CN | disclosed |
| WO-2019116324-A1 | TRIAZOLOBENZAZEPINES AS VASOPRESSIN V1A RECEPTOR ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2019-06-20 | — | — | WO | disclosed |
| US-20190048013-A1 | VASOPRESSIN RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | Neumora Therapeutics, Inc. | 2019-02-14 | — | — | US | disclosed |
| WO-2005079808-A1 | TRIAZOLE DERIVATIVES WHICH INHIBIT VASOPRESSIN ANTAGONISTIC ACTIVITY | PFIZER LIMITED (GB) | 2005-09-01 | — | — | WO | disclosed |
| EP-1558598-A1 | TRIAZOLE COMPOUNDS FOR THE TREATMENT OF DYSMENORRHOEA | Pfizer Limited (GB) | 2005-08-03 | — | — | EP | disclosed |
| US-20050049255-A1 | Therapeutic combinations | PFIZER INC | 2005-03-03 | — | — | US | disclosed |
| WO-2004108138-A1 | THERAPEUTIC COMBINATIONS COMPRISING PDE INHIBITORS AND VASOPRESSIN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF DYSMENORRHOEA | PFIZER LIMITED (GB) | 2004-12-16 | — | — | WO | disclosed |
| WO-2004108138-A1 | THERAPEUTIC COMBINATIONS COMPRISING PDE INHIBITORS AND VASOPRESSIN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF DYSMENORRHOEA | PFIZER LIMITED (GB) | 2004-12-16 | — | — | WO | disclosed |
| US-20040186091-A1 | A bi-heterocycle-4H-2,3,5,10b-tetraaza-benzo[e]azulene derivatives; for therapy of dysmenorrhoea, anxiety disorder, asthma, atherosclerosis, cardiac failure, cardiovascular disease, cataract, central nervous system disease, motion sickness, Raynaud's disease, rheumatoid arthritis; chemical synthesis | PFIZER INC | 2004-09-23 | — | — | US | disclosed |
| WO-2004074291-A1 | TRIAZOLE COMPOUNDS USEFUL IN THERAPY | PFIZER LIMITED (GB) | 2004-09-02 | — | — | WO | disclosed |
| WO-2004074291-A1 | TRIAZOLE COMPOUNDS USEFUL IN THERAPY | PFIZER LIMITED (GB) | 2004-09-02 | — | — | WO | disclosed |
| US-20040162278-A1 | Triazole compounds useful in therapy | PFIZER INC | 2004-08-19 | — | — | US | disclosed |
| WO-2004037809-A1 | TRIAZOLE COMPOUNDS FOR THE TREATMENT OF DYSMENORRHOEA | PFIZER LIMITED (GB) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162278-A1 | Triazole compounds useful in therapy | AVPR2, AVPR1B, AVPR1A | MALT1 2524/4885GPR119 284/4885RIPK1 4321/4885 |
| US-11298363-B2 | Triazolobenzazepines as vasopressin V1a receptor antagonists | AVPR1B, AVPR1A, AVPR2 | MALT1 2199/4885GPR119 116/4885RIPK1 3014/4885 |
| US-11186577-B2 | Vasopressin receptor antagonists and products and methods related thereto | AVPR1B, AVPR1A, AVPR2 | MALT1 3973/4885GPR119 152/4885RIPK1 4377/4885 |
| US-20190048013-A1 | VASOPRESSIN RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | AVPR1B, AVPR1A, AVPR2 | MALT1 3973/4885GPR119 152/4885RIPK1 4377/4885 |
| US-11858943-B2 | Vasopressin receptor antagonists and products and methods related thereto | AVPR1B, AVPR1A, AVPR2 | MALT1 3973/4885GPR119 152/4885RIPK1 4377/4885 |
| US-20050049255-A1 | Therapeutic combinations | AVPR2, AVPR1B, AVPR1A | MALT1 4542/4885GPR119 536/4885RIPK1 4784/4885 |
| US-20040186091-A1 | A bi-heterocycle-4H-2,3,5,10b-tetraaza-benzo[e]azulene derivatives; for therapy of dysmenorrhoea, anxiety disorder, asthma, atherosclerosis, cardiac failure, cardiovascular disease, cataract, central nervous system disease, motion sickness, Raynaud's disease, rheumatoid arthritis; chemical synthesis | CNR1, NR1H2, OXER1 | MALT1 98/4885GPR119 1673/4885RIPK1 4308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.